Teva’s More Convenient Copaxone Puts Payors In A Bind
Teva Pharmaceutical’s recent launch of a more convenient formulation of its soon-to-be-generic multiple sclerosis blockbuster Copaxone puts payors in a quandary. They must choose whether to position it favorably on formularies, similar to the flexible standing that the original daily injection often enjoys, or restrict access to it in a way that has teeth.
You may also be interested in...
Teva’s multiple sclerosis drug Copaxone lost patent protection about three weeks ago. But according to some analysts an immediate generic substitution is still up in the air and the company has not lost the opportunity to capitalize in the interim by switching patients to a new three-injections-a-week formulation.
Amid challenges in the generics sector, the proposed merger of Forest and Actavis creates uncertainty about how the companies will market their primary care drugs.
FDA “has not to date had any questions that would indicate our application is off track,” CEO Wheeler says as Momenta and partner Sandoz gear up for the launch.